Concord Biotech (CONCORDBIO) investor relations material

Executive summary

• Q2 FY27 consolidated revenue rose 25.1% YoY to Rs 309.1 crore; H1 revenue increased 25.6% to Rs 566.6 crore, with growth across products and geographies.

• Q2 consolidated net profit was Rs 69.6 crore; H1 net profit was Rs 127.3 crore, up 19.0% YoY.

Financial highlights

• Consolidated Q2 revenue from operations was Rs 30,907.02 lakhs vs Rs 24,705.75 lakhs in Q2 FY26; net profit was Rs 6,957.20 lakhs vs Rs 6,306.28 lakhs.

• Consolidated H1 revenue from operations was Rs 56,655.92 lakhs vs Rs 45,104.51 lakhs; net profit was Rs 12,726.87 lakhs vs Rs 10,712.07 lakhs.

• Q2 EBITDA was Rs 104.4 crore, up 18.0% YoY; H1 EBITDA was Rs 186.8 crore vs Rs 149.9 crore.

• Standalone Q2 revenue was Rs 31,231.38 lakhs and net profit Rs 7,571.39 lakhs; H1 revenue was Rs 57,283.09 lakhs and net profit Rs 13,690.75 lakhs.

Outlook and guidance

• FY27 revenue growth expected slightly above the historical 18%-19% range, supported by launches, market-share gains and growth initiatives.

• API growth expected to build on its historical 18%-19% range; new APIs, formulations, injectables and CDMO are expected to add growth.

• EBITDA margin expected to move from 33%-34% toward 38%-39% as Stellon and injectables ramp; medium-term range indicated at 38%-40%.

• Management expects gross-margin recovery as input-cost pressures ease; effective tax rate expected at 24%-25% for the rest of FY27 and FY28.